BridgeBio's founder saw biotech VCs exclusively funding high-risk "home run" platforms. He built a company to acquire therapies for smaller rare genetic diseases—"singles and doubles"—that were ignored. Aggregating these de-risks the portfolio and creates a major market opportunity.

The current public market isn't an indiscriminate bull run. It rewards strong data and punishes failure, creating an environment where deep-domain specialty investors, who can discern true value, thrive over generalists.

The current market prefers funding drugs for clinically validated targets, reducing 'biology risk'. However, this floods popular targets with dozens of competitors, creating immense 'commercial risk' where only one or two can truly succeed in a crowded field, a potentially worse gamble.

Priovant strategically focuses on rare autoimmune diseases affecting tens of thousands of patients, rather than ultra-rare conditions. This approach addresses significant unmet needs while creating a substantial cumulative market opportunity by aggregating multiple such indications.

Cogent's CEO argues that biotech investors often overlook proven modalities like targeted therapies in favor of "sexy" categories like AI or gene therapy. He believes that even if a drug doesn't fit a hyped trend, impressive clinical outcomes will ultimately win, making these less-hyped areas underappreciated.

The value of a late-stage asset is not just its scientific promise. Acquirers and investors look for a clear definition of unmet medical need, a straightforward clinical development pathway, and a well-defined regulatory landscape to de-risk the path to market.

Contrary to most industries, scale is not a decisive advantage in drug discovery. Wellington's Jean Hynes notes that small, nimble biotech companies discover roughly half of all new drugs. This creates a perpetual opportunity for investors to back small firms that can generate massive value.

The strategy is to acquire biotech companies at valuations justified by a narrow clinical indication (e.g., premature ejaculation). The massive return comes from the "free option" of the much larger off-label consumer market (e.g., all men wanting to last longer) that is not priced in.

In crowded fields like oncology, most companies flock to a few validated ideas, like kids chasing a soccer ball. Delpha Therapeutics' CEO Kevin Marks argues the real opportunity lies in pioneering novel biology in the wide-open parts of the field, creating a strategic advantage and potential scarcity effect.